Literature DB >> 24360587

The effect of graft configuration on 30-day failure of infrapopliteal bypasses.

Bao-Ngoc Nguyen1, Richard F Neville2, Mustafa Abugideiri3, Richard Amdur4, Anton N Sidawy2.   

Abstract

BACKGROUND: Despite advances in endovascular techniques, infrapopliteal bypasses are still required for limb salvage. Short-term graft patency is an important outcome parameter reflecting technical considerations and acute graft thrombosis. Both are important prerequisites for long-term patency. In this analysis, we compared the 30-day patency of all conduit configurations for infrapopliteal bypasses.
METHODS: All primary infrapopliteal bypasses from the American College of Surgeons-National Surgical Quality Improvement Program database between 2005 and 2010 were divided into six groups: (1) great saphenous vein (GSV); (2) prosthetic conduit (prosthetic); (3) prosthetic conduit with a distal anastomotic venous adjunct (ADJ), such as a cuff or patch (prosthetic + ADJ); (4) composite graft of prosthetic and a vein segment (composite); (5) spliced autogenous vein (spliced vein); and (6) arm vein. Thirty-day graft failure, patient demographics, and operative details were compared among groups. A multivariate model was used for statistical analysis.
RESULTS: A total of 5375 infrapopliteal bypasses were analyzed by conduit: GSV, 3983 (75%); prosthetic, 898 (17%); spliced vein, 160 (3%); prosthetic + ADJ, 112 (2%); arm vein, 93 (2%); and composite, 91 (2%). The difference among groups in demographics and comorbidities was not statistically significant. Perioperative mortality rates were similar among different conduits. After adjusting for sex, age, weight, race, and previous cardiac surgery, the bypass conduit had a significant independent association with 30-day graft patency (P = .006). The GSV failure rate was 7.5%. Composite had a significantly higher 30-day failure rate (15.4%, P = .006). There was no significant difference in 30-day failure rate of spliced vein (5.6%, P = .37) or arm vein (4.3%, P = .24) conduits compared with GSV. Prosthetic had significantly higher 30-day failure rate than GSV (10.5%, P = .004). The addition of adjuvant venous tissue at the distal anastomosis of prosthetic bypasses did not significantly improve their 30-day patency (failure rate of 9.8% for prosthetic + ADJ and 10.5% for prosthetic). There was no significant difference in graft patency between alternative venous conduits (arm vein/spliced vein) and prosthetic + ADJ.
CONCLUSIONS: Venous conduits (GSV, spliced vein, arm vein) deliver the best 30-day patency for infrapopliteal bypasses, and GSV remains the most commonly used graft. Prosthetic grafts had a higher 30-day failure rate. Composite grafts should be abandoned because their early patency is not better than pure prosthetic conduits. The addition of a distal venous adjunct did not seem to improve acute prosthetic graft patency, which may reflect lack of effect on thrombogenicity rather than the myointimal hyperplastic response that effects long-term failure of infrapopliteal bypass.
Copyright © 2014 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24360587     DOI: 10.1016/j.jvs.2013.10.091

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

Review 1.  Current Status of Arterial Revascularization for the Treatment of Critical Limb Ischemia in Infrainguinal Atherosclerotic Disease.

Authors:  Ahmet Yuksel; Yusuf Velioglu; Mustafa Cagdas Cayir; Gencehan Kumtepe; Orcun Gurbuz
Journal:  Int J Angiol       Date:  2018-01-22

2.  Long-term outcomes of infrainguinal bypass surgery for patients with diabetes mellitus and tissue loss.

Authors:  Heekyung Jung; Jayun Cho; Hyung-Kee Kim; Jihye Kim; Seung Huh
Journal:  Ann Surg Treat Res       Date:  2014-12-26       Impact factor: 1.859

3.  Immunological Aspects Involved in the Degeneration of Cryopreserved Arterial Allografts.

Authors:  Mario González-Gay; Rocío López-Martínez; Sara Busto-Suárez; Mariel Estefanía Riedemann-Wistuba; María Ángeles Menéndez-Herrero; Francisco Álvarez-Marcos; Manuel Alonso-Pérez; Rebeca Alonso-Arias
Journal:  Front Surg       Date:  2020-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.